Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Chronic Myeloid Leukemia
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Leukemia (2150
)
Acute Myelogenous Leukemia (1007
)
Acute Lymphocytic Leukemia (418
)
Chronic Lymphocytic Leukemia (326
)
B Acute Lymphoblastic Leukemia (193
)
T Acute Lymphoblastic Leukemia (39
)
Childhood B Acute Lymphoblastic Leukemia (37
)
Hairy Cell Leukemia (23
)
Chronic Myelomonocytic Leukemia (20
)
Prolymphocytic Leukemia (17
)
Acute Promyelocytic Leukemia (12
)
Juvenile Myelomonocytic Leukemia (5
)
Chronic Eosinophilic Leukemia (4
)
Chronic Neutrophilic Leukemia (3
)
Leukemia (2150
)
Acute Myelogenous Leukemia (1007
)
Acute Lymphocytic Leukemia (418
)
Chronic Lymphocytic Leukemia (326
)
B Acute Lymphoblastic Leukemia (193
)
T Acute Lymphoblastic Leukemia (39
)
Childhood B Acute Lymphoblastic Leukemia (37
)
Hairy Cell Leukemia (23
)
Chronic Myelomonocytic Leukemia (20
)
Prolymphocytic Leukemia (17
)
Acute Promyelocytic Leukemia (12
)
Juvenile Myelomonocytic Leukemia (5
)
Chronic Eosinophilic Leukemia (4
)
Chronic Neutrophilic Leukemia (3
)
›
Associations
(267)
News
Trials
VERI cancer hierarchy
Reset Filters
BCR-ABL1 fusion
Chronic Myeloid Leukemia
BCR-ABL1 fusion
Chronic Myeloid Leukemia
dasatinib
Sensitive: A1 - Approval
dasatinib
Sensitive
:
A1
dasatinib
Sensitive: A1 - Approval
dasatinib
Sensitive
:
A1
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
asciminib
Sensitive: A1 - Approval
asciminib
Sensitive
:
A1
asciminib
Sensitive: A1 - Approval
asciminib
Sensitive
:
A1
No biomarker
Chronic Myeloid Leukemia
No biomarker
Chronic Myeloid Leukemia
omacetaxine mepesuccinate
Sensitive: A1 - Approval
omacetaxine mepesuccinate
Sensitive
:
A1
omacetaxine mepesuccinate
Sensitive: A1 - Approval
omacetaxine mepesuccinate
Sensitive
:
A1
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
ponatinib
Sensitive: A1 - Approval
ponatinib
Sensitive
:
A1
ponatinib
Sensitive: A1 - Approval
ponatinib
Sensitive
:
A1
No biomarker
Chronic Myeloid Leukemia
No biomarker
Chronic Myeloid Leukemia
ponatinib
Sensitive: A1 - Approval
ponatinib
Sensitive
:
A1
ponatinib
Sensitive: A1 - Approval
ponatinib
Sensitive
:
A1
ABL1 T315I
Chronic Myeloid Leukemia
ABL1 T315I
Chronic Myeloid Leukemia
ponatinib
Sensitive: A1 - Approval
ponatinib
Sensitive
:
A1
ponatinib
Sensitive: A1 - Approval
ponatinib
Sensitive
:
A1
No biomarker
Chronic Myeloid Leukemia
No biomarker
Chronic Myeloid Leukemia
busulfan
Sensitive: A1 - Approval
busulfan
Sensitive
:
A1
busulfan
Sensitive: A1 - Approval
busulfan
Sensitive
:
A1
BCR-ABL1 fusion
Chronic Myeloid Leukemia
BCR-ABL1 fusion
Chronic Myeloid Leukemia
asciminib
Sensitive: A1 - Approval
asciminib
Sensitive
:
A1
asciminib
Sensitive: A1 - Approval
asciminib
Sensitive
:
A1
BCR-ABL1 fusion
Chronic Myeloid Leukemia
BCR-ABL1 fusion
Chronic Myeloid Leukemia
nilotinib
Sensitive: A1 - Approval
nilotinib
Sensitive
:
A1
nilotinib
Sensitive: A1 - Approval
nilotinib
Sensitive
:
A1
BCR-ABL1 fusion
Chronic Myeloid Leukemia
BCR-ABL1 fusion
Chronic Myeloid Leukemia
bosutinib
Sensitive: A1 - Approval
bosutinib
Sensitive
:
A1
bosutinib
Sensitive: A1 - Approval
bosutinib
Sensitive
:
A1
BCR-ABL1 fusion
Chronic Myeloid Leukemia
BCR-ABL1 fusion
Chronic Myeloid Leukemia
imatinib
Sensitive: A1 - Approval
imatinib
Sensitive
:
A1
imatinib
Sensitive: A1 - Approval
imatinib
Sensitive
:
A1
BCR-ABL1 V299L
Chronic Myeloid Leukemia
BCR-ABL1 V299L
Chronic Myeloid Leukemia
bosutinib
Resistant: A2 - Guideline
bosutinib
Resistant
:
A2
bosutinib
Resistant: A2 - Guideline
bosutinib
Resistant
:
A2
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.